Journal of Oncology

Epigenetic Alterations in Tumorigenesis


Publishing date
01 Jan 2023
Status
Published
Submission deadline
26 Aug 2022

Lead Editor
Guest Editors

1Southern University of Science and Technology, Shenzhen, China

2Clark Atlanta University, Atlanta, USA

3Harvard Medical School, Boston, USA


Epigenetic Alterations in Tumorigenesis

Description

Epigenetics is defined as functional and inheritable changes in the regulation of gene activity and expression without altering the primary DNA sequence, which is dynamic and susceptible to environmental exposures. Epigenetic regulation includes DNA methylation and demethylation, as well as posttranslational modifications of histones, chromatin remodeling, nucleosome positioning, and non-coding RNAs. Both epigenetic and genetic alterations contribute to cancer initiation and progression. In the process of tumor formation and development, epigenetic alteration has increasingly attracted attention. Aberrant epigenetic regulation contributes to cancer development through its involvement in tumor growth, apoptosis, senescence, invasion, metastasis, stemness, and drug resistance.

Similar to cancer genetics, cancer epigenetics has advanced due to high-throughput technology to characterize the epigenetic changes at the global and single-molecular levels. Epigenetic alterations may promote genetic mutations and genomic rearrangements in cancer, although the mechanisms involved are yet to be elucidated. A greater understanding of epigenetics and the therapeutic potential of intervention into these processes is necessary to help clinical treatment of cancer. More importantly, there are quite a number of scientific and pragmatic challenges to discovering epigenetic drugs as we are just beginning to understand the complexities of epigenetic events.

The aim of this Special Issue is to collate findings associated with epigenetic factors as ‘drivers’ or regulators of tumorigenesis. We welcome both original research and review articles.

Potential topics include but are not limited to the following:

  • DNA methylation in cancer
  • Histone modification in cancer
  • Non-coding RNA in cancer
  • Epigenetic reprogramming in tumor metastasis
  • Epigenetic alteration in cancer chemoresistance
  • Epigenetic factors as therapeutic targets
  • Epigenetic factors as diagnostic markers
  • The development of compounds that target enzymes involved in regulating the epigenome
  • Epigenetic regulation of cancer stem cell formation and maintenance
  • Epigenetic regulation of tumor microenvironment

Articles

  • Special Issue
  • - Volume 2022
  • - Article ID 3842547
  • - Research Article

Comprehensive Pan-Cancer Analysis Reveals the Role of UHRF1-Mediated DNA Methylation and Immune Infiltration in Renal Cell Carcinoma

Xiao Pan | Caiqin Li | ... | Susu Wu
  • Special Issue
  • - Volume 2022
  • - Article ID 6883140
  • - Research Article

Downregulation of hsa-miR-30b-3p Inhibits the Oncogenicity of Lung Adenocarcinoma by Targeting the METTL7B Gene

Ning Li | Rui Li | ... | Yiqing Qu
  • Special Issue
  • - Volume 2022
  • - Article ID 9054983
  • - Research Article

Identification and Validation of a GPX4-Related Immune Prognostic Signature for Lung Adenocarcinoma

Zhenxing Feng | Bo Li | ... | Jianwen Qin
  • Special Issue
  • - Volume 2022
  • - Article ID 3465459
  • - Research Article

Long Noncoding RNA H19 Derived from M2 Tumor-Associated Macrophages Promotes Bladder Cell Autophagy via Stabilizing ULK1

Yuanyuan Guo | Wei Sun | ... | Rui Wang
  • Special Issue
  • - Volume 2022
  • - Article ID 8268719
  • - Research Article

M2 Tumor Associate Macrophage- (TAM-) Derived lncRNA HISLA Promotes EMT Potential in Bladder Cancer

Yuanyuan Guo | Zhong Li | ... | Rui Wang
  • Special Issue
  • - Volume 2022
  • - Article ID 7346460
  • - Research Article

Long Noncoding RNA MMP2-AS1 Contributes to Progression of Renal Cell Carcinoma by Modulating miR-34c-5p/MMP2 Axis

Bo Fan | Yunfeng Niu | ... | Aili Zhang
Journal of Oncology
 Journal metrics
See full report
Acceptance rate6%
Submission to final decision136 days
Acceptance to publication68 days
CiteScore3.900
Journal Citation Indicator-
Impact Factor-

We have begun to integrate the 200+ Hindawi journals into Wiley’s journal portfolio. You can find out more about how this benefits our journal communities on our FAQ.